Targeting the unfolded protein response, XBP1, and the NLRP3 inflammasome in fibrosis and cancer

Cancer Biology and Therapy

Volumn 15, Issue 4, 2014, Pages 452-462

  Overley Adamson, Beth ^a   Artlett, Carol M ^b   Stephens, Connie ^c   Sassi Gaha, Sihem ^b   Weis, Ransome D ^d   Thacker, James D ^b,c  

^a CARES (Center for Animal Referral and Emergency Services)   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c TherimuneX Pharmaceuticals Inc   (United States)

^d Doylestown Hospital   (United States)

Author keywords

Cancer; Chemotherapy; ER; Fibrosis; Immune; Inflammasome; NLRP3; Oncogenesis; UPR; XBP1

Indexed keywords

ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORAMBUCIL; CRYOPYRIN; CYCLOPHOSPHAMIDE; DERACOXIB; DOXORUBICIN; FLUOROURACIL; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; LOMUSTINE; NACLYNAMIDE; PIROXICAM; PREDNISONE; TOCERANIB; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; CARRIER PROTEIN; DNA BINDING PROTEIN; NLRP3 PROTEIN, HUMAN; REGULATORY FACTOR X TRANSCRIPTION FACTORS; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR STRESS RESPONSE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; DISULFIDE BOND; EMBRYO; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL DOG; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; UNFOLDED PROTEIN RESPONSE; ANIMAL; BONE NEOPLASMS; C57BL MOUSE; CASE REPORT; CELL CULTURE; COLORECTAL NEOPLASMS; DOG; DOG DISEASES; FIBROSIS; LYMPHOMA, NON-HODGKIN; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PILOT STUDY; VETERINARY;

ANIMALS; BONE NEOPLASMS; CARRIER PROTEINS; CELLS, CULTURED; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; DOG DISEASES; DOGS; ENDOPLASMIC RETICULUM STRESS; FEMALE; FIBROSIS; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; LYMPHOMA, NON-HODGKIN; MALE; MICE, INBRED C57BL; NEOPLASMS; OSTEOSARCOMA; PILOT PROJECTS; PROTEIN SORTING SIGNALS; TRANSCRIPTION FACTORS; UNFOLDED PROTEIN RESPONSE;

EID: 84897498263     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27820     Document Type: Article

References (33)

1. Chakrabarti A, Chen AW, Varner JD. A review of the mammalian unfolded protein response. Biotechnol Bioeng 2011; 108:2777-93; PMID:21809331; http://dx.doi.org/10.1002/bit.23282
2. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13:343-51; PMID:22430787; http://dx.doi.org/10.1038/ni.2224
3. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol 2011; 11:213-20; PMID:21350580; http://dx.doi.org/10.1038/nri2936
4. Chu J, Thomas LM, Watkins SC, Franchi L, Núñez G, Salter RD. Cholesterol-dependent cytolysins induce rapid release of mature IL-1beta from murine macrophages in a NLRP3 inflammasome and cathepsin B-dependent manner. J Leukoc Biol 2009; 86:1227-38; PMID:19675207; http://dx.doi.org/10.1189/jlb. 0309164
5. Dostert C, Guarda G, Romero JF, Menu P, Gross O, Tardivel A, Suva M-L, Stehle J-C, Kopf M, Stamenkovic I, et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009; 4:e6510; PMID:19652710; http://dx.doi.org/10.1371/journal.pone.0006510
6. Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 2006; 126:1135-45; PMID:16990137; http://dx.doi.org/10.1016/j.cell.2006.07.033
7. Thomas PG, Dash P, Aldridge JR Jr., Ellebedy AH, Reynolds C, Funk AJ, Martin WJ, Lamkanfi M, Webby RJ, Boyd KL, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009; 30:566-75; PMID:19362023; http://dx.doi.org/10.1016/j.immuni.2009.02.006
8. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008; 105:9035-40; PMID:18577586; http://dx.doi.org/10.1073/pnas.0803933105
9. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320:674-7; PMID:18403674; http://dx.doi.org/10.1126/science.1156995
10. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-56; PMID:18604214; http://dx.doi.org/10.1038/ni.1631
11. Gasse P, Riteau N, Charron S, Girre S, Fick L, Pétrilli V, Tschopp J, Lagente V, Quesniaux VFJ, Ryffel B, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009; 179:903-13; PMID:19218193; http://dx.doi.org/10.1164/ rccm.200808-1274OC
12. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-32; PMID:16407890; http://dx.doi.org/10.1038/nature04515
13. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A. Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer's pathology. J Cell Mol Med 2008; 12(6A):2255-62; PMID:18793350; http://dx.doi.org/10.1111/j.1582- 4934.2008.00496.x
14. Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, Grant EP, Coyle AJ, Misaghi A, Hoffman HM, et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 2009; 284:12762-71; PMID:19258328; http://dx.doi.org/10.1074/jbc.M806084200
15. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C, Ting JP. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207:1045-56; PMID:20385749; http://dx.doi.org/10.1084/jem.20100050
16. Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 2011; 63:3563-74; PMID:21792841; http://dx.doi.org/10.1002/art.30568
17. Thacker JD, Brown MA, Rest RF, Purohit M, Sassi-Gaha S, Artlett CM. 1-Peptidyl-2-arachidonoyl-3-stearoyl-sn-glyceride: an immunologically active lipopeptide from goat serum (Capra hircus) is an endogenous damage-associated molecular pattern. J Nat Prod 2009; 72:1993-9; PMID:19835390; http://dx.doi.org/10.1021/np900360m
18. Thacker JD, Balin BJ, Appelt DM, Sassi-Gaha S, Purohit M, Rest RF, Artlett CM. NLRP3 inflammasome is a target for development of broad-spectrum anti-infective drugs. Antimicrob Agents Chemother 2012; 56:1921-30; PMID:22290938; http://dx.doi.org/10.1128/AAC.06372-11
19. Majumder M, Huang C, Snider MD, Komar AA, Tanaka J, Kaufman RJ, Krokowski D, Hatzoglou M. A novel feedback loop regulates the response to endoplasmic reticulum stress via the cooperation of cytoplasmic splicing and mRNA translation. Mol Cell Biol 2012; 32:992-1003; PMID:22215619; http://dx.doi.org/10.1128/MCB.06665-11
20. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008; 454:455-62; PMID:18650916; http://dx.doi.org/10.1038/nature07203
21. Luckett EM. THX314: Intravenous toxicity study in female C57Bl/6 mice. MPI Research, Inc. Mattawan, MI 49071 February 25, 2010.
22. Paetzel M, Karla A, Strynadka NCJ, Dalbey RE. Signal peptidases. Chem Rev 2002; 102:4549-80; PMID:12475201; http://dx.doi.org/10.1021/cr010166y
23. Bryan NB, Dorfleutner A, Rojanasakul Y, Stehlik C. Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain. J Immunol 2009; 182:3173-82; PMID:19234215; http://dx.doi.org/10.4049/jimmunol.0802367
24. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469:221-5; PMID:21124315; http://dx.doi.org/10.1038/nature09663
25. Koong AC, Chauhan V, Romero-Ramirez L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther 2006; 5:756-9; PMID:16861911; http://dx.doi.org/10.4161/cbt.5.7.2973
26. Mimura N, Fulciniti M, Gorgun G, Tai Y-T, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, et al. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood 2012; 119:5772-81; PMID:22538852; http://dx.doi.org/10.1182/blood-2011-07-366633
27. Liu Y, Zhang X, Liang Y, Yu H, Chen X, Zheng T, Zheng B, Wang L, Zhao L, Shi C, et al. Targeting X box-binding protein-1 (XBP1) enhances sensitivity of glioma cells to oxidative stress. Neuropathol Appl Neurobiol 2011; 37:395-405; PMID:21138464; http://dx.doi.org/10.1111/j.1365-2990.2010.01155.x
28. Andres SA, Wittliff JL. Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue. Endocrine 2011; 40:212-21; PMID:21858728; http://dx.doi.org/10.1007/s12020-011-9522-x
29. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, Mori K, Glimcher LH, Denko NC, Giaccia AJ, et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res 2004; 64:5943-7; PMID:15342372; http://dx.doi.org/10.1158/0008-5472.CAN-04-1606
30. Iwakoshi NN, Pypaert M, Glimcher LH. The transcription factor XBP-1 is essential for the development and survival of dendritic cells. J Exp Med 2007; 204:2267-75; PMID:17875675; http://dx.doi.org/10.1084/jem.20070525
31. Lenna S, Farina AG, Martyanov V, Christmann RB, Wood TA, Farber HW, Scorza R, Whitfield ML, Lafyatis R, Trojanowska M. Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Arthritis Rheum 2013; 65:1357-66; PMID:23400395; http://dx.doi.org/10.1002/art.37891
32. Derk CT, Artlett CM, Jimenez SA. Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study. Clin Rheumatol 2006; 25:831-4; PMID:16435160; http://dx.doi.org/10.1007/ s10067-005-0177-y
33. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33:1113-6; PMID:16622904